- Home
- ZVSA
as 07-26-2024 4:00pm EST
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SOMERVILLE |
| Market Cap: | 3.3M | IPO Year: | N/A |
| Target Price: | $240.00 | AVG Volume (30 days): | 281.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1145.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.41 - $79.80 | Next Earning Date: | 08-19-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ZyVersa Therapeutics Inc. News
ZVSA Breaking Stock News: Dive into ZVSA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
GlobeNewswire
8 days ago
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
GlobeNewswire
18 days ago
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
GlobeNewswire
2 months ago
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
GlobeNewswire
2 months ago
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
GlobeNewswire
3 months ago
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
GlobeNewswire
4 months ago
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
GlobeNewswire
4 months ago
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Compare ZVSA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ZVSA ZyVersa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.